Abstract
Survival results after treatment of advanced epithelial ovarian cancer are disappointing. While cisplatin alone or in combination produces response rates of approximately 60–80% in advanced disease, the initial optimism that overall cure rates in ovarian cancer would be substantially improved has not been fulfilled. The duration of relapse-free time has been increased over that achieved with single agent alkylating agents, but only 5–10% more patients are long term disease-free survivors [1]. Overall cure rates in advanced disease remain about 20–30% [2–4]. One strategy that has been generally pursued in improving treatment outcomes in solid tumours has been to attempt to combine effective therapies sequentially or concurrently, particularly if their toxicities are non-overlapping.
Keywords
- Ovarian Cancer
- Ovarian Carcinoma
- Epithelial Ovarian Cancer
- Minimal Residual Disease
- Advanced Ovarian Cancer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Neijt, J.P., ten Bokkel Huinink, W.W., van den Burg, M.E.L. et al (1991) Long term results of chemotherapy in advanced (FIGO Stages III or IV) ovarian cancer. Int. Gynecol Cancer Soc., (abstract), 36.
Neijt, J.P., ten Bokkel Huinink, W.W., van den Burg, M.E.L. et al (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma, J. Clin. Oncol. 51157–68.
Vogl, S.E., Pagano, M., Kaplan, B.H. et al. (1983) Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumour burdens. Cancer 512024–30.
Omura, G.A., Blessing, J.A., Ehrlich, C.E. et al. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study.Cancer 571725–30.
Dembo, A.J. (1984) Abdominopelvic radiotherapy in ovarian cancer: a 10-year experience. Cancer 55,2285–90.
Fuks, Z., Rizel, S. and Biran, S. (1988) Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of Stage III ovarian carcinoma. J. Clin. Oncol 6, 509–16.
Bruzzone, M., Repetto, L., Chiara, S. et al. (1990) Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol. Oncol 38,392–5.
Lambert, H.E., Rustin, G.J.S., Gregory, W.M. and Nelstrop, A.E. (1993) A randomised trial comparing single agent carbo- platin with carboplatin followed by radiotherapy for advanced ovarian cancer. A North Thames Ovary Group Study.J. Clin. Oncol 11, 440–8.
Mangioni, C., Epis, A., Vassena, L. et al (1987) Radiotherapy (RT) versus chemotherapy (CH) as second line treatment of minimal residual disease (MRD) in advanced epithelial ovarian cancer (EOC) Proceedings of the International Gynecological Cancer Society October, Amsterdam.
Lawton, P., Luesley, D., Blackledge, G. et al (1990) A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Clin. Oncol 2,4–9.
Hacker, N.F., Berek, J.S., Burnison, C.M. et al (1985) Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet. Gynecol 6560–6.
Chiara, S., Orsatti, M., Pranzone, P. et al (1991) Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer. Clin. Oncol 3,340–4.
Peters III W.A., Blasko, J.C., Bagley Jr, C.M. et al (1986) Salvage therapy with whole- abdominal irradiation in patients with advanced carcinoma of the ovary previously treated by combination chemotherapy. Cancer 58880–2.
Hoskins, W.J., Lichter, A.S., Whittington, R. et al (1985) Whole abdominal and pelvic irradiation in patients with minimal disease at second-look surgical reassessment for ovarian carcinoma. Gynecol Oncol 20271–80.
Greiner, R., Goldhirsch, A., Davis, B.W. et al (1984) Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy and second-look laparotomy. J. Cancer Res. Clin. Oncol 107, 94–8.
Piver, M.S., Barlow, J.J., Lee, P.T. and Vongtama, V. (1975) Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy and radiation therapy. Am. J. Obstet, Gynecol 122, 355–7.
Hainsworth, J.D., Malcolm, A., Johnson, D.H. et al (1983) Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy. Obstet. Gynecol 61, 619–23.
Schray, M.F., Martinez, A., Howes, A.E. et al (1988) Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J. Clin. Oncol 61433–9.
Reddy, S., Hartsell, W., Graham, J. et al (1989)Whole-abdomen radiation therapy in ovarian carcinoma: its role as a salvage therapeutic modality. Gynecol Oncol 35 307–13.
Kuten, A., Stein, M., Steiner, M. et al. (1988) Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma.Int. J. Radiat. Oncol. Biol. Phys. 14 273–9.
Linstadt, D.E., Stern, J.L., Quivey, J.M. et al. (1990) Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma. Gynecol. Oncol. 36, 327–30.
Solomon, H.J., Atkinson, K.H., Coppleson, J.V.M. et al. (1988) Ovarian carcinoma: abdominopelvic irradiation following reexploration. Gynecol. Oncol 31 396–401.
Kong, J.S., Peters, L.J., Wharton, J.T. et al (1988) Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: tolerance and toxicity. Int. J. Radiat. Oncol Biol Phys. 14 737–43.
Rosen, E.M., Goldberg, I.D., Rose, C. et al (1986) Sequential multi-agent chemotherapy and whole abdominal irradiation for stage III ovarian carcinoma. Radiother. Oncol 1 223–32.
Rothenberg, M.L., Ozols, R.F., Glatstein, E. et al (1992) Dose-intensive induction therapy with cyclophosphamide, cisplatin, and con- solidative abdominal radiation in advanced- stage epithelial ovarian cancer.J. Clin. Oncol 10 727–34.
Haie, C., Pejovic-Lenfant, M.H., George, M. et al (1989) Whole abdominal irradiation following chemotherapy in patients with minimal residual disease after second look surgery in ovarian carcinoma. Int. J. Radiat. Oncol Biol Phys. 1715–19.
Cain, J.M., Russell, A.H., Greer, B.E. et al (1988) Whole abdomen radiation for minimal residual epithelial ovarian carcinoma after surgical resection and maximal first-line chemotherapy. Gynecol Oncol 29168–75.
Kersh, C.R., Randall, M.E., Constable, W.C. et al (1988) Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma. Gynecol Oncol 31,113–20.
Goldhirsch, A., Greiner, R., Dreher, E. et al (1988) Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer 62, 40–7.
Rustin, G.J.S., Minton, M., Southcott, B. et al (1987) Surgery, chemotherapy and whole abdominal radiotherapy in the management of advanced ovarian carcinoma. Clin. Radiol 38,269–72.
Menczer, J., Modan, M., Brenner, J. et al (1986) Abdominopelvic irradiation for Stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy. Gynecol Oncol 24, 149–54.
Morgan, L., Chafe, W., Mendenhall, W. and Marcus, R. (1988) Hyperfractionation of whole- abdomen radiation therapy: salvage treatment of persistent ovarian carcinoma following chemotherapy. Gynecol Oncol 31122–34.
Coltart, R.S., Nethersell, A.B.W. and Brown C.H. (1986) A pilot study of high dose abdominopelvic radiotherapy following surgery and chemotherapy for Stage III epithelial carcinoma of the ovary. Gynecol Oncol 23105–10.
Shelly, W.E., Carmichael, J.C., Brown, L.B. et al (1988) Adriamycin and cisplatin in the treatment of Stage III and IV epithelial ovarian carcinoma. Gynecol Oncol 29208–21.
Dembo, A.J. and Bush, R.S. (1982) Choice of postoperative therapy based on prognostic factors. Int. J. Radiat. Oncol Biol Phys. 8, 893–7.
Dembo, A.J., Bush, R.S. and Brown, T.C. (1982) Clinicopathological correlates in ovarian cancer. Bulletin du Cancer (Paris) 69292–8.
Carey, M., Dembo, A.J., Fyles, A.W. and Simm, J. (1993) Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int. J. Gynecol Cancer 3 24–35.
Lindner, H., Willich, H. and Atzinger, A. (1990) Primary adjuvant whole abdominal irradiation in ovarian carcinoma. Int. J. Radiat. Oncol Biol Phys. 191203–6.
Ledermann, J.A., Dembo, A.J., Sturgeon, J.F.G. et al (1991) Outcome of patients with unfavourable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation. Gynecol Oncol 41 30–5.
Whelan, T.J., Dembo, A.J., Bush, R.S. et al (1992) Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int. J. Radiat. Oncol Biol Phys. 22,853–8.
Hoskins, W.J., Rubin, S.C. (1991) Surgery in the treatment of patients with advanced ovarian cancer. Semin. Oncol 18213–21.
Louie, K.G., Behrens, B.C., Kinsella, T.J. et al (1985) Radiation survival parameters of anti- neoplastic drug-sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 452110–15.
Withers, H.R., Taylor, J.M.G. and Maciejewski, B. (1988) The hazard of accelerated tumour donogen repopulation during radiotherapy. Acta Oncol 27,131–46.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
Thomas, G.M. (1995). Radiotherapy as salvage or consolidation therapy in advanced epithelial ovarian cancer. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_27
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive